Pyxis Oncology, Inc. (PYXS) Insider Trading Disclosures
Pyxis Oncology, Inc. (PYXS) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: PYXS
CIK: 1782223
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young LLP
Auditor SinceSince 12/31/2020 12:00:00 AM
Lead Engagement PartnerJoel Wagner
Audit LocationBoston, Massachusetts, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| PRE 14A | 2026-10-09 | 2026-10-09 | PRE 14A | 0001193125-26-419208 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-10-09 | — | SCHEDULE 13G/A Filing | 0000919574-26-006818 | View SEC Doc Filr Page |
| 4/A | 2026-10-09 | 2026-10-01 | 4/A Filing | 0000919574-26-006815 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-10-05 | — | SCHEDULE 13G Filing | 0001104659-26-113597 | View SEC Doc Filr Page |
| 4 | 2026-10-02 | 2026-10-01 | 4 Filing | 0000919574-26-006609 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-10-02 | — | SCHEDULE 13G/A Filing | 0000919574-26-006608 | View SEC Doc Filr Page |
| 8-K | 2026-10-01 | 2026-09-29 | FORM 8-K | 0001437749-26-031767 | View SEC Doc Filr Page |
| 424B5 | 2026-10-01 | — | FORM 424B5 | 0001437749-26-031667 | View SEC Doc Filr Page |
| 424B5 | 2026-09-29 | — | FORM 424B5 | 0001437749-26-031480 | View SEC Doc Filr Page |
| 424B5 | 2026-09-29 | — | FORM 424B5 | 0001437749-26-031470 | View SEC Doc Filr Page |
| 8-K | 2026-09-09 | 2026-09-09 | 8-K | 0001193125-26-385901 | View SEC Doc Filr Page |
| 4 | 2026-09-08 | 2026-09-04 | 4 | 0001193125-26-384391 | View SEC Doc Filr Page |
| 8-K | 2026-09-08 | 2026-09-03 | 8-K | 0001193125-26-384386 | View SEC Doc Filr Page |
| 424B2 | 2026-08-28 | — | 424B2 | 0001193125-26-372221 | View SEC Doc Filr Page |
| EFFECT | 2026-08-27 | — | EFFECT Filing | 9999999995-26-002786 | View SEC Doc Filr Page |
| 4 | 2026-08-20 | 2026-08-20 | 4 | 0001193125-26-359525 | View SEC Doc Filr Page |
| S-3 | 2026-08-20 | — | S-3 | 0001193125-26-359246 | View SEC Doc Filr Page |
| 4 | 2026-08-14 | 2026-08-12 | 4 | 0001193125-26-352206 | View SEC Doc Filr Page |
| 10-Q | 2026-08-13 | 2026-06-30 | 10-Q | 0001193125-26-347913 | View SEC Doc Filr Page |
| 8-K | 2026-08-13 | 2026-08-13 | 8-K | 0001193125-26-347911 | View SEC Doc Filr Page |
| 3 | 2026-07-10 | 2026-06-30 | 3 Filing | 0000919574-26-004386 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-07-10 | — | SCHEDULE 13G Filing | 0000921895-26-001796 | View SEC Doc Filr Page |
| 4 | 2026-07-02 | 2026-06-30 | 4 | 0001193125-26-294708 | View SEC Doc Filr Page |
| 8-K | 2026-07-02 | 2026-06-30 | 8-K | 0001193125-26-294613 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-07-02 | — | SCHEDULE 13G/A Filing | 0000919574-26-004255 | View SEC Doc Filr Page |